Five Recent Deals Show ADCs Aren’t Cooling Off For Summer

While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.

summer_cloudsresized.jpg
A review of this summer's dealmaking sees a continued interest in ADCs

Biopharmaceutical companies remained on the hunt for cancer antibody-drug conjugate assets this summer, as deals revolving around ADCs accounted for five of 12 cancer-related deals, according to Biomedtracker.

Key Takeaways
  • Continuing a multi-year trend of hectic dealmaking in the cancer antibody-drug conjugate space, five alliances centered on ADC candidates and R&D were announced this summer

ADCs have been a significant driver of biopharma dealmaking for several years now. Two of 2023’s four largest M&A transactions were big pharma buyouts of ADC specialists – Pfizer Inc.’s $43bn acquisition of Seagen Inc. that March, followed by AbbVie Inc.’s $10.1bn takeout of ImmunoGen, Inc. in November. (Also see "The Biggest M&A Announcements Of 2023 Show Deals Are Getting Bigger" - Scrip, 15 January, 2024

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Pharma Left Hanging After US/UK Trade Pact

 
• By 

An ‘historic economic prosperity deal’ does not include the sector.

More from Business

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By 

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By 

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By 

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.